Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aminophylline→

Aminophylline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
317-34-0
Molecular formula
C16H24N10O4
Molecular weight
420.43 g/mol
Drug class
Methylxanthine bronchodilatortheophylline–ethylenediamine complex
Mechanism of action
Theophylline produces bronchodilation through non-selective phosphodiesterase inhibition and antagonism of adenosine receptors, increasing intracellular cyclic AMP and reducing bronchial smooth-muscle tone. Aminophylline dissociates to theophylline and ethylenediamine; theophylline is the pharmacologically active bronchodilator moiety.
Indications / reported uses
  • Treatment of reversible airflow obstruction in selected patients when other bronchodilator options are inadequate; use requires serum theophylline concentration monitoring because of the narrow therapeutic index

Sources: US DailyMed — Aminophylline injection · NLM MeSH — Aminophylline · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aminophylline Environmental Risk Assessment (ERA) (the Aminophylline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.